Sterling Capital Management
DMRA

Sterling Capital Management’s Damora Therapeutics DMRA Stock Holding History

Sterling Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28.9K Buy
1,359
+895
+193% +$25.3K ﹤0.01% 2012
2026
Q2 		$12.1K Buy
+464
New +$11.2K ﹤0.01% 2120

Other funds holding DMRA

STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Parkside Financial Bank & Trust
Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Sterling Capital Management's DMRA Position: Q3 2026 in Review

Sterling Capital Management increased its Damora Therapeutics (DMRA) stake by 193% in Q3 2026, buying an estimated $25.3K and bringing the position to 1,359 shares worth $28.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2012.

Sterling Capital Management first reported a position in DMRA in Q2 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

  • Sterling Capital Management held 1,359 shares of Damora Therapeutics worth $28.9K as of Q3 2026.
  • Sterling Capital Management bought 895 Damora Therapeutics shares in Q3 2026, an estimated $25.3K.
  • Damora Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2012 holding.
  • Sterling Capital Management first reported a position in Damora Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.